Edition:
India

GSK starts late-stage trial for experimental antibiotic


Monday, 28 Oct 2019 

Oct 28 (Reuters) - GlaxoSmithKline PLC ::GSK STARTS A PHASE III CLINICAL PROGRAMME FOR A POTENTIAL FIRST-IN-CLASS ANTIBIOTIC, GEPOTIDACIN.GSK SAYS TRIAL INVESTIGATING USE OF GEPOTIDACIN FOR UNCOMPLICATED URINARY TRACT INFECTION AND UROGENITAL GONORRHOEA.GSK - PHASE III PROGRAMME HAS TWO STUDIES, ONE COMPARING GEPOTIDACIN TO CEFTRIAXONE PLUS AZITHROMYCIN, SECOND TO COMPARE GEPOTIDACIN TO NITROFURANTOIN.GSK SAYS FIRST RESULTS FROM PROGRAMME ARE EXPECTED BY THE END OF 2021.